Announcement of Federal Funding Opportunity

Summary

I. GENERAL INFORMATION

Unlike other award mechanisms of the Prostate Cancer Research Program (PCRP), the Clinical Trial Award, expected to be released in fiscal year 2005 (FY05), will be executed through two separate awards, the Clinical Trial Development Award in FY04 and, pending receipt of funds for FY05, the Clinical Trial Award in FY05. Proposals for the first award, the Clinical Trial Development Award, are being requested in this program announcement. Recipients of the Clinical Trial Development Award in FY04 will be required to submit proposals, clinical protocols, and consent forms to compete for the Clinical Trial Award in FY05. However, the Clinical Trial Award anticipated for FY05 will be open to all eligible applicants with clinical trials relevant to prostate cancer treatment, diagnosis, detection, or prevention. Funding for Clinical Trial Development Awards in FY04 is for up to $100,000 per award inclusive of both direct and indirect costs for up to 1 year. Funding will be disbursed in two equal installments, pending proposal, clinical protocol, and consent form submission. Funding for Clinical Trial Awards in FY05 is anticipated to be up to $1 million (M) per award over a 3-year period of performance, with approximately $5M expected to be available for this award mechanism.

A. Title of Award: Clinical Trial Development Award (CTDA).

B. Program Name: Department of Defense FY04 PCRP.

C. Funding Opportunity Number: PC04-CTDA.

D. Agency Name: US Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP), 1077 Patchel Street, Fort Detrick, Maryland 21702-5024.

E. Agency Contact(s):

1. Questions related to the Program, proposal format, or required documentation may be addressed to the CDMRP at:

   Phone: 301-619-7079
   Fax: 301-619-7792
   E-mail: cdmrp.pa@det.amedd.army.mil
   Mail: Commander
   US Army Medical Research and Materiel Command
   ATTN: MCMR-PLF (PC04-CTDA)
   1077 Patchel Street (Building 1077)
   Fort Detrick, MD 21702-5024

2. Questions related to electronic submission: The help line phone number is 301-682-5507 and is also provided on the web. Other help desk contact information is:

   Website: http://cdmrp.org/proposals (the proposal submission website)
   E-mail: help-proposals-cdmrp@cdmrp.org
F. Anticipated Instrument Type(s): Grants/Cooperative Agreements.

G. Catalog of Federal Domestic Assistance (CFDA) Number(s): 12.420; Military Medical Research and Development.

H. Website Address to Access Application Package: Proposals must be submitted electronically at http://cdmrp.org/proposals. The website contains all the information, forms, documents, and links you will need to apply.

I. Award/Regulatory Approval: Once an award is made, the applicant may not use, employ, or subcontract for the use of any human subjects, human anatomical substances, or use of laboratory animals without express written permission from the applicable USAMRMC Regulatory Compliance and Quality (RCQ) office. USAMRMC RCQ will forward these express written approvals directly to the applicant with a copy furnished to the institution’s Sponsored Programs Office (or equivalent).

II. FUNDING OPPORTUNITY DESCRIPTION

The intent of the Clinical Trial Development Award is to provide support to establish the necessary collaborations and develop the necessary research resources that will serve as a foundation for investigator-initiated clinical trials. The goal of these awards is the development of Phase I or Phase II clinical trial(s) that will have a major impact on the treatment, diagnosis, detection, or prevention of prostate cancer. As such, they should focus on new interventions and not on the refinements of existing interventions (e.g., optimizing timing or dosage regimens).

III. AWARD INFORMATION

- Type of award: grant/cooperative agreement.
- Approximately $1.5M is available for the FY04 Clinical Trial Development Award mechanism.
- Funding for Clinical Trial Development Awards can be requested for up to $100,000 for 1 year, inclusive of both direct and indirect costs. Funding will be disbursed in two equal installments, one installment at the time of award and the second installment contingent upon submission of a compliant FY05 Clinical Trial Award proposal, clinical protocol, and consent form. Funds may not be used to support laboratory or preclinical research.
- Approximately 15 Clinical Trial Development Award proposals will be funded.
- Clinical Trial Development awardees will be required to submit a proposal, clinical protocol, and consent form for the Clinical Trial Award in December 2004 according to guidance provided in the PCRP Clinical Trial Award Program Announcement. The Clinical Trial Award in FY05 is anticipated to fund up to five awards for up to $1M per award over a 3-year period of performance, with approximately $5M expected to be available for this award mechanism, pending receipt of funds.
- Please note that full Clinical Trial Award proposals may be submitted in FY05 without prior submission or receipt of a FY04 Clinical Trial Development Award.
- Please note that there is no guarantee that funds will be available for Clinical Trial Awards in FY05.
IV. ELIGIBILITY INFORMATION

A. Applicants: Applicants must be independent investigators at an eligible institution.

B. Institutions: Eligible institutions include for-profit, non-profit, public, and private organizations.

C. Cost Sharing: It is expected that institutions will cost share. Please see “Major Equipment” located in Subsection V.F.2.c of the Full Text of Program Announcement for details.

D. Other Eligibility Criteria: Please see the Full Text of Program Announcement description for details regarding duplicate submissions, applications from Historically Black Colleges and Universities/Minority Institutions, and administrative compliance issues.

V. PROPOSAL PREPARATION AND SUBMISSION INFORMATION

A. Proposal Information: Applicants are required to submit the Proposal Information prior to upload of the proposal. Complete the Proposal Information as described at http://cdmrp.org/proposals.

B. Proposal Preparation: All proposals must be converted into an electronic PDF (Portable Document Format) file for electronic proposal submission. Please see the Full Text of Program Announcement for details.

C. Submission Dates and Times: Deadline Date: April 13, 2004. Proposals must be approved on the CDMRP eReceipt system by the Contract Representative at the applicant’s institution’s Sponsored Programs Office (or equivalent) by 5:00 p.m. (Eastern time).

D. Electronic Submission Requirements: Electronic submission is required. No paper copy submissions will be accepted. Proposals must be submitted electronically at http://cdmrp.org/proposals. Please see the Full Text of Program Announcement for details.

VI. PROPOSAL REVIEW INFORMATION

Clinical Trial Development Award proposals will receive a single level of review. Proposals for the Clinical Trial Development Award will be reviewed by the PCRP Integration Panel to determine which proposals best fulfill the intent of the award mechanism.

VII. AWARD ADMINISTRATION INFORMATION

A. Award Notices and Administrative Requirements: Details of award notification procedures, and administrative requirements including Regulatory documents (Certificate of Environmental Compliance, Research Involving Human Subjects and/or Anatomical Substances, Research Involving Animals, and Safety Program Plan) can be found in the Full Text of Program Announcement.

B. Reporting Requirements: Annual reporting requirements apply.
I. GENERAL INFORMATION

A. Title of Award: Clinical Trial Development Award (CTDA).

B. Program Name: Department of Defense (DOD) Fiscal Year 2004 (FY04) Prostate Cancer Research Program (PCRP).

C. Funding Opportunity Number: PC04-CTDA.

D. Agency Name: US Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP), 1077 Patchel Street, Fort Detrick, Maryland 21702-5024.

E. Agency Contact(s):

1. Questions related to the Program, proposal format, or required documentation: Applicants should submit questions as early as possible. Every effort will be made to answer questions within 5 working days.

   Phone: 301-619-7079
   Fax: 301-619-7792
   E-mail: cdmrp.pa@det.amedd.army.mil
   Mail: Commander
   US Army Medical Research and Materiel Command
   ATTN: MCMR-PLF (PC04-CTDA)
   1077 Patchel Street (Building 1077)
   Fort Detrick, MD 21702-5024

2. Questions related to electronic submission: Help lines will be available to answer specific questions regarding the preparation of proposals for electronic submission or the process of electronic submission. The help line phone number is 301-682-5507 and is also provided on the web. Other help desk contact information is:

   Website: https://cdmrp.org/proposals (the proposal submission website)
   E-mail: help-proposals-cdmrp@cdmrp.org

F. Anticipated Instrument Type(s): The USAMRMC implements its extramural research program predominantly through the award of grants and cooperative agreements. More information on these funding instruments may be obtained by request from:

   Fax: 301-619-2937
   E-mail: qa.baa@det.amedd.army.mil
   Mail: Director
   US Army Medical Research Acquisition Activity
   ATTN: MCMR-AAA
   820 Chandler Street
   Fort Detrick, MD 21702-5014
G. Catalog of Federal Domestic Assistance (CFDA) Number 12.420: Military Medical Research and Development.

H. Website to Access Application Package: Proposals must be submitted electronically at https://cdmrp.org/proposals. This website will contain all the information, forms, documents, and links you will need to apply. If you experience difficulties in downloading documents, contact the CDMRP as indicated in Subsection E.1 above.

I. Award/Regulatory Approval: Once an award is made, the applicant may not use, employ, or subcontract for the use of any human subjects, human anatomical substances, or use of laboratory animals without express written permission from the applicable USAMRMC Regulatory Compliance and Quality (RCQ) office. USAMRMC RCQ will forward these express written approvals directly to the applicant with a copy furnished to the institution’s Sponsored Programs Office (or equivalent).

II. FUNDING OPPORTUNITY DESCRIPTION

A. Program History: The Clinical Trial Development Award is part of the DOD PCRP, which was established in FY97 to promote innovative research directed toward eliminating prostate cancer. Appropriations for the PCRP since FY97 total $565 million (M). The program history of the FY97-03 PCRP is shown in Table 1. The FY04 appropriation is $85M. The Clinical Trial Development Award is a new award mechanism for the PCRP and is being offered for the first time in FY04.

Table 1: History of the DOD’s Peer Reviewed PCRP

<table>
<thead>
<tr>
<th>Program History</th>
<th>FY97-01</th>
<th>FY02</th>
<th>FY03¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congressional Appropriations for PCRP</td>
<td>$310M</td>
<td>$85M</td>
<td>$85M</td>
</tr>
<tr>
<td>Total Proposals Received</td>
<td>2,734</td>
<td>699</td>
<td>834</td>
</tr>
<tr>
<td>Total Proposals Funded</td>
<td>651</td>
<td>146</td>
<td>213</td>
</tr>
</tbody>
</table>

¹Award negotiations will be finalized by September 2004.

B. Program Objectives: The objectives of the FY04 PCRP are to (1) prevent prostate cancer, (2) detect prostate cancer in its earliest stages of development, (3) cure prostate cancer, and (4) improve the quality of life for individuals and their families living with prostate cancer.

C. Award Mechanism Description: The Clinical Trial Award for Phase I and/or Phase II clinical trials, anticipated for release in FY05, will be executed through two separate awards: the Clinical Trial Development Award in FY04 and, pending receipt of funds, the Clinical Trial Award in FY05. Proposals for the first award, the Clinical Trial Development Award, are being requested in this program announcement. Recipients of the Clinical Trial Development Award in FY04 will be required to submit proposals, clinical protocols, and consent forms to compete for the Clinical Trial Award in FY05. However, the FY05 Clinical Trial Award will be open to all eligible applicants with clinical trial proposals relevant to prostate cancer treatment, diagnosis, detection, or prevention.

Due to the scope and magnitude of the PCRP Clinical Trial Awards, the Clinical Trial Development Award has been instituted to provide support to establish the necessary collaborations and develop clinical protocols to provide a foundation for investigator-initiated clinical trials. The goal of these awards is to provide a foundation for the rapid execution of Phase I or Phase II clinical trial(s) that will have a major impact on the treatment, diagnosis, detection, or prevention of prostate cancer. As such,
they should focus on new interventions and not on the refinements of existing interventions (e.g.,
optimizing timing or dosage regimens).

The Clinical Trial Development Award proposal should briefly describe:

- The objective and rationale of the proposed clinical trial, including any preclinical science
  and preliminary clinical research relevant to the trial;
- The relevance of the proposed clinical trial to prostate cancer treatment, diagnosis, detection,
or prevention;
- The proposed intervention(s) to be tested in the clinical trial, with a brief description, as
  appropriate, of its:
  - Source,
  - Investigational New Drug (IND) status,
  - Availability of the substance in sufficient quantity under current Good Manufacturing
    Practices (cGMP) production,
  - Dosing,
  - Mechanisms of action, and
  - Preclinical/clinical evidence of efficacy;
- A preliminary estimate of sample size for the clinical trial, a preliminary patient
  accrual/recruitment schedule, and evidence of access to appropriate patient population(s);
- A plan for the development of a clinical protocol and consent form, and the outline of a plan
  for obtaining both internal scientific and local Institutional Review Board (IRB) reviews for
  the clinical protocol and consent form at the highest level possible within the institution, up to
  and including preliminary IRB approval if available at your institution, by the time of the
  Clinical Trial Award proposal submission;
- An outline of a clinical trial management plan; and
- Evidence of preliminary institutional commitment to the proposed clinical trial.

The Clinical Trial Development Award has been instituted to facilitate the funding of a quality clinical
trial and the rapid accrual of patients into the trial through a well-developed clinical protocol. The
purpose of the Clinical Trial Development Award is not to obtain preliminary data or to conduct studies
to support the rationale for the proposed clinical trial; therefore, funds may not be used to support
laboratory or preclinical research. One product of the Clinical Trial Development Award will be the
requirement to submit a PCRP Clinical Trial Award proposal, clinical protocol, and consent form for
competitive peer and programmatic review in FY05. In addition, funds from the Clinical Trial
Development Award may also be used to:

- Support meetings, teleconferences, and travel among participating investigators to develop the
  clinical trial and associated protocol and consent form;
- Furnish salary support during the clinical protocol development;
- Develop and implement a data management, real-time communications, or administration plan
  for the proposed clinical trial;
- Reimburse the Principal Investigator’s (PI’s) institution for costs associated with conducting the
  IRB review of the proposed clinical protocol and consent form;
- Provide other costs directly associated with planning and developing the clinical trial;
- Coordinate consent forms and other IRB issues between different institutions for multi-institutional trials;
- Resolve intellectual property and material rights among institutions, companies, and investigators;
- Develop definitive statistical plans; and
- Develop sources and obtain letters affirming intervention supply or availability.

The proposal, clinical protocol, and consent form must all be submitted as part of the application for the Clinical Trial Award in FY05. Failure to submit a Clinical Trial Award proposal in FY05 after receipt of a FY04 Clinical Trial Development Award will result in a forfeit of the second installment of the Clinical Trial Development Award funding. Selection to receive a FY04 Clinical Trial Development Award and submission of an FY05 Clinical Trial Award proposal do not guarantee a FY05 Clinical Trial Award. The FY05 Clinical Trial Award will also be open to all eligible applicants with clinical trials relevant to prostate cancer treatment, diagnosis, detection, or prevention irrespective of receipt of a FY04 Clinical Trial Development Award.

### III. AWARD INFORMATION

Funding for the Clinical Trial Development Awards in FY04 is for up to $100,000 per award inclusive of both direct and indirect costs for up to 1 year; funds will be disbursed in two equal installment payments, pending proposal, protocol, and consent form submission. Funds from both installments of the Clinical Trial Development Award can cover administrative support including salary, meetings and related travel among participating investigators, database generation and software development, purchase of computers, design of websites, teleconferences, and other costs directly associated with planning, development, and review of the clinical trial or the clinical protocol and consent form. Travel costs may not exceed $1,800 per investigator. *Funds may not be used to support laboratory or preclinical research.*

Disbursement of the Clinical Trial Development Award funds will be made in two equal installments. The first installment will be made at the time of the award; the second installment will be made after the submission of a compliant Clinical Trial Award proposal, clinical protocol, and consent form. **Failure to submit a Clinical Trial Award in FY05 after receipt of a FY04 Clinical Trial Development Award will result in a forfeit of the second installment of the Clinical Trial Development Award funding.**

Clinical Trial Development awardees will be required to submit a proposal for the Clinical Trial Award in December 2004 according to guidance provided in the FY05 PCRP Clinical Trial Award Program Announcement. Funding for Clinical Trial Award in FY05 is anticipated to be up to $1M per award over a 3-year period of performance, with approximately $5M expected to be available for this award mechanism. The FY05 Clinical Trial Award will be open to all eligible applicants with clinical trials relevant to prostate cancer treatment, diagnosis, detection, or prevention irrespective of submission of an FY04 Clinical Trial Development Award.

The nature of this Program does not allow for renewal of grants or supplementation of existing grants. Approximately $1.5M is available to the PCRP for the Clinical Trial Development Awards. It is anticipated that approximately 15 proposals will be funded.

*Please note that there is no guarantee that funds will be available for Clinical Trial Awards in FY05.*
IV. ELIGIBILITY INFORMATION

A. Applicants: Applicants must be independent investigators at an eligible institution.

B. Institutions: Eligible institutions include for-profit, non-profit, public, and private organizations. Examples include universities, colleges, hospitals, laboratories, companies, and agencies of local, state, and federal governments. The USAMRMC is especially interested in receiving applications from Historically Black Colleges and Universities/Minority Institutions (HBCU/MI).

C. Cost Sharing: It is expected that institutions will cost share. Please see full details under “Major Equipment” located in Subsection V.F.2.c.

D. Other Eligibility Criteria:

1. Duplicate Submissions: Submission of the same research project to the FY04 PCRP under different award mechanisms or to other CDMRP programs is discouraged. However, if similar research projects are submitted to this and other FY04 program announcements within the CDMRP, the applicant must provide a strong justification for submitting duplicate proposals and the proposal’s relevance to prostate cancer in the “Proposal Relevance Statement.” The Government reserves the right to reject duplicative proposals.

2. HBCU/MI: A goal of the DOD is to allocate funds for the CDMRP’s peer reviewed research to fund proposals from HBCU/MI. This provision is based upon guidance from Executive Orders. Proposals submitted to the DOD are assigned HBCU/MI status if the submitting institution is so designated by the Department of Education on the date that the program announcement is released. The Department of Education list is posted on the CDMRP website under Minority Institutions at http://cdmrp.army.mil/funding/pdf/mipcrp112003.pdf.

3. Administrative Compliance Issues: Compliance guidelines have been designed to ensure the presentation of all proposals in an organized and easy-to-follow manner. Reviewers expect to see a consistent, prescribed format for each proposal. Nonadherence to format requirements makes proposals difficult to read, may be perceived as an attempt to gain an unfair competitive advantage, and may result in proposal rejection or a lower global priority score.

The following will result in administrative rejection of the entire proposal prior to review:

- Proposal body exceeds page limit.
- Proposal body is missing.
- Detailed cost estimate is missing.
- Proposal is incomplete after the deadline.
- Required administrative documentation is not included.

For any other sections of a proposal with a defined page limit, any pages over the specified limit will be removed from the proposal and not forwarded for review.

Unless specifically requested by the Government, any material submitted after the submission deadline will not be forwarded for review.

---

1 Executive Orders 12876, 12900, and 13021
V. PROPOSAL PREPARATION AND SUBMISSION INFORMATION

A. Proposal Components Summary: This subsection is a summary of submission requirements. Details, URLs, and other links are provided in the appropriate subsections of this program announcement.

The PI is responsible for uploading the following information:

- **Proposal Information:** The Proposal Information consists of two parts, both of which are entered as data fields. A Letter of Intent is generated when Part 1 of the Proposal Information is saved.

- **Statement of Work (SOW) and Proposal Abstracts:** The SOW, Technical Abstract, and Public Abstract are each entered as a separate data field.

- **Proposal:** The proposal is uploaded as a PDF (Portable Document Format) file under the “Required Files” tab.

- **Budget Information:** The budget information is uploaded as a PDF file under the “Required Files” tab.

- **Regulatory Documents:** The Certificate of Environmental Compliance and the Principal Investigator Safety Program Assurance form are each uploaded as separate PDF files under the “Required Files” tab.

The Contract Representative or institutional official responsible for sponsored program administration (or equivalent) from the applicant’s institution is responsible for the following:

- **US Army Medical Research Acquisition Activity (USAMRAA) Documents:** The institute’s currently negotiated “Rate Agreement,” “Certifications and Assurances for Assistance Agreements,” and the “Representations for Assistance Agreements” are to be uploaded as separate PDF files under the Contract Representative’s “My Profile” tab.

- **Approval:** The Contract Representative or institutional official responsible for sponsored program administration must provide approval of all proposal components (Proposal Information, SOW, Abstracts, Proposal, Budget Information, and Regulatory documents). Contract Representative approval must occur prior to the submission deadline of 5:00 p.m. (Eastern time) April 13, 2004. The eReceipt system will not accept data entry, file uploads, or approvals submitted after the 5:00 p.m. Eastern time April 13, 2004 deadline.

B. Proposal Information: Applicants are required to submit the Proposal Information, Parts 1 and 2, prior to upload of the proposal and the budget information. Complete the Proposal Information as described in [https://cdmrp.org/proposals](https://cdmrp.org/proposals). The Proposal Information must include the e-mail address of a representative from the Sponsored Programs Office (or equivalent) who is authorized to negotiate on behalf of the institute.

- **Letter of Intent:** An electronic Letter of Intent should be submitted by February 17, 2004. To accomplish this, the applicant should complete Part 1 of the Proposal Information section at [https://cdmrp.org/proposals](https://cdmrp.org/proposals), then save the information by clicking on the “Save and Forward Letter of Intent” button. This information may be changed at any time until the applicant submits the final Proposal Information by clicking on the “Submit Final” button.
C. SOW – 11,400-character limit, including spaces (approximately two pages): The SOW is captured as a data field under the “SOW/Abstract” tab in the CDMRP eReceipt system. To submit the SOW, the applicant may either type in the SOW or “cut and paste” it from a word processing application into the data field. Sample SOWs can be found at https://cdmrp.org/samples.cfm.

The SOW is a concise restatement of the research proposal that outlines, step by step, how each of the major goals or objectives of the proposed clinical trial development will be accomplished during the timeline for which the USAMRMC will provide financial support.

As appropriate, the SOW should:

- Describe the work to be accomplished as tasks (tasks may relate to specific aims),
- Identify the timeline and milestones for the work over the period of the proposed effort,
- Indicate the numbers of research subjects (animal or human) and/or anatomical samples projected or required for each task,
- Identify methods, and
- Identify outcomes, products, and deliverables for each phase of the project.

D. Proposal Abstracts – 5,700-character limit, including spaces (approximately one page), for each abstract: Both a structured technical abstract and a public (nontechnical) abstract are required. These abstracts are vitally important to the review process.

Each abstract must contain the title of the proposal and the name of the PI. Each abstract must be submitted as a data field under the “SOW/Abstracts” tab of the CDMRP eReceipt system. Applicants can either type in their abstracts, or “cut and paste” them from a word processing application into the respective data fields. Do not include figures or tables in either abstract. Spell out all Greek or other non-English letters.

Abstracts of all funded proposals will be posted on the CDMRP website at http://cdmrp.army.mil/. Thus, proprietary or confidential information should not be included in the abstracts.

1. Technical Abstract: Sample technical abstracts can be found at https://cdmrp.org/samples.cfm. The structured technical abstract should provide a clear and concise overview of the proposed work, including the background, objective or hypothesis and its supporting rationale, specific aims of the study, study design, and significance of the proposed work to the Program’s goals.

Use the outline below for preparing the structured technical abstract.

- Background: Provide a brief statement of the ideas and reasoning behind the proposed clinical trial. Briefly describe the studies that led to the proposed clinical trial.
- Intervention: State the intervention to be tested. Provide evidence or rationale that supports the intervention.
- Trial Design: Briefly describe the proposed clinical trial, including proposed patient sample size, accrual, and outcome measures. Indicate the phase (I, I/II, or II) of the clinical trial.
- Relevance: Provide a brief statement explaining the relevance of the proposed clinical trial to prostate cancer treatment, diagnosis, detection, or prevention.
2. **Public Abstract:** Sample public abstracts can be found at [https://cdmrp.org/samples.cfm](https://cdmrp.org/samples.cfm). The public abstract is intended to communicate the purpose of, and rationale for, the study to non-scientific audiences. The public abstract is an important component of the proposal review process because consumer advocates, who are part of the review and funding decision process, use this abstract as a part of their review. It must be composed in a way to make the scientific objectives and rationale for the proposal understandable to non-scientifically trained readers. **The public abstract should not be a duplicate of the technical abstract**, but should describe the goals and objectives of the research project, and its relevance to the Program.

In addition to describing the project, the public abstract must answer the following questions:

1. What are the ideas and reasoning behind the proposed clinical trial?
2. What will be the ultimate applicability of the clinical trial to prostate cancer?
   - What types of patients will it help and how?
   - What are the potential clinical applications, benefits, and risks?
   - What is the projected time it may take to achieve a consumer-related outcome?

E. **Proposal:**

1. **Format:** All proposals must be converted into an electronic PDF file for electronic submission. Proposals must be uploaded under the “Required Files” tab of the CDMRP eReceipt system. Applicants unfamiliar with the preparation of PDF files are encouraged to acquire appropriate software and learn the process before the submission deadline. To prepare proposals for PDF submission, the instructions in this subsection must be followed carefully.

The proposal must be clear and legible and conform to the following guidelines:

- **Type Font:** 12 point, 10 pitch.
- **Type Density:** No more than 15 characters per inch. (For proportional spacing, the average for any representative section of text should not exceed either 15 characters per inch or 114 characters per line.)
- **Spacing:** Single-spaced between lines of text, no more than five lines of type within a vertical inch.
- **Margins:** Minimum of 0.5-inch top, bottom, right, and 1-inch left.
- **Color, Resolution, and Multimedia Objects:** Proposals may include color, high resolution, or multimedia objects (e.g., MPEG, WAV, or AVI files) embedded in the PDF files; however, these items must not exceed 15 seconds in length and a size of 10 megabytes (MB). Since some reviewers work from black and white printed copies, applicants may wish to include text in the proposal directing the reviewer to the electronic file for parts of the proposal that may be difficult to interpret when printed in black and white.
- **Spell out all acronyms the first time they are used.** One page following the proposal body is allocated to spell out acronyms, abbreviations, and symbols.
- **Language:** English.
- **Print Area:** 7.0 x 10.0 inches (approximately 18 cm x 25.5 cm).
2. Title/Referral Page: No page limit. Complete the Title/Referral Page, which can be downloaded at https://cdmrp.org/programAnnouncements.cfm. Complete each section as described:

a. Proposal title (up to 160 characters).
b. Proposal log number (this will be automatically provided when the Proposal Information is completed and saved).
c. PI’s full name (first, middle initial, last).
d. Submitting institution.
e. Award mechanism: Type in “Clinical Trial Development Award.” Indicate the clinical trial phase (Phase I, I/II, or II).
f. Indicate if this is a NEW proposal or DUPLICATE proposal to other FY04 CDMRP program announcements proposal to this Program.
g. Keyword descriptive technical terms: To assist the staff in assigning proposals, please specify the subject area of the proposal. Also, list specific keywords and descriptive technical terms that would best describe the technical aspects of the project.
h. Conflicts of interest: To avoid real and apparent conflicts of interest during the review process, list the names of all scientific participants in the proposal including consultants, collaborators, and subawardees. In addition, list the names of other individuals outside the scope of this proposal who may have a conflict of interest in review of this proposal. Provide the following information for each participant: name, institutional affiliation(s), and, if applicable, his or her role(s) on the proposed project.

3. Table of Contents/Checklist: Start section on a new page; one-page limit. Prepare a Table of Contents/Checklist, with page numbers. Number all pages consecutively at the bottom center, beginning with the Title/Referral Page.

4. Proposal Relevance Statement: Start section on a new page; one-page limit. Applicants should state explicitly how the proposed work will have a major impact on the treatment of prostate cancer. If this proposal is duplicative of a proposal submitted to another FY04 CDMRP program announcement, provide a strong justification for submitting duplicate proposals and the proposal’s relevance to prostate cancer.

5. Proposal Resubmission Statement: Not applicable for Clinical Trial Development Award submissions.

6. Main Body: Start section on a new page; six-page limit inclusive of any figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, cartoons, and other relevant information needed to judge the proposal. It is the responsibility of the investigator to clearly articulate how the proposed plan for a clinical trial meets the intent of the mechanism. The proposal body should address the review criteria as outlined in Subsection VI.B of this program announcement and should include the following six parts.
Describe the proposed clinical trial using the outline provided below:

- State the objective and rationale of the proposed clinical trial, including any preclinical science and preliminary clinical research relevant to the trial;
- State the relevance of the proposed clinical trial to prostate cancer treatment, diagnosis, detection, or prevention;
- As appropriate, describe the proposed intervention(s) to be tested in the clinical trial, with a brief description of its source, IND status, availability of the substance in sufficient quantity under cGMP production, dosing, mechanism(s) of action, and preclinical/clinical efficacy;
- Provide a description of the patient population(s), an estimated sample size for the clinical trial, and a preliminary patient accrual/recruitment schedule;
- Outline the plan for the development of a clinical protocol and consent form and for obtaining both internal scientific and local IRB reviews at the highest level possible within the institution, up to and including preliminary IRB approval if available at your institution, by the time of the Clinical Trial Award proposal submission;
- Describe the preliminary management plan for the clinical trial, including key participants and their contributions (additional information on collaborators can be included in the Biographical Sketch section, see item 9 below).
- Provide some evidence that the institution will support the proposed clinical trial.

7. Abbreviations: Start section on a new page; one-page limit. Provide a list of all acronyms, abbreviations, and symbols used.

8. References: Start section on a new page; no page limit. List all relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

9. Biographical Sketches: Three-page limit per individual. Biographical sketches should be included for each of the key personnel listed on the budget page, including collaborating investigators and support staff. These documents are a critical component of the review process. Incomplete or missing biographical sketches may result in lower priority scores. The Biographical Sketch form may be used. Use of this form is not mandatory, but the information requested shall be presented in a similar format.

10. Existing/Pending Support: Start section on a new page; no page limit. List on a separate page the titles, time commitments, supporting agencies, durations, and levels of funding for all existing and pending research projects involving the PI and key personnel. If no support exists, state “none.” Proposals submitted under this program announcement should not duplicate other funded research projects.

11. Facilities/Equipment Description: No page limit. Describe the facilities available for performance of the proposed research/services. Describe the institutional commitment, including any additional facilities or equipment proposed for purchase or available for use at no cost to the USAMRMC. Indicate if Government-owned facilities or equipment are proposed for use.

12. Questionnaires, Survey Instruments, or Clinical Protocols: No page limit. Include an appropriately titled page listing the documents you have included in this section. Submission of a preliminary protocol is not required with the Clinical Trial Development Award proposal.
13. **Publications and/or Patent Abstracts: Five-document limit.** Include up to five relevant publication reprints and/or patent abstracts. A patent abstract should provide a non-proprietary description of the patent application. If more than five such items are included in the submission, the extra items will not be reviewed.

14. **Administrative Documentation: No page limit.** Submit only material specifically requested or required in this program announcement. **This section is not for additional figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, cartoons, or other relevant information needed to judge the proposal.** Unrequested material that is submitted may be construed as an attempt to gain a competitive advantage and will be removed; it may be grounds for administrative rejection of the proposal.

   The first item in this section must be a list of all the items included in the Administrative Documentation section.

   - Provide letter(s) of support from any collaborating individuals or institutions.
   - Provide letter(s) of commitment from institutions proposing to participate in the clinical trial.

   All administrative documentation must be incorporated into the electronic PDF version of your proposal. Support documentation will not be accepted separately from the electronic proposal submission. All documents or letters requiring signatures must be signed and then incorporated into the submitted proposal.

F. **Budget Information:** Budget Information includes the [Detailed Cost Estimate forms and Budget Justification](#). Budget Information is uploaded under the “Required Files” tab of the CDMRP eReceipt system.

   1. **Funding Restrictions:** Funding for the Clinical Trial Development Awards in FY04 is for up to $100,000 per award inclusive of both direct and indirect costs for up to 1 year; funds will be disbursed in two installment payments, pending proposal, clinical protocol, and consent form submission. Funds from both installments of the Clinical Trial Development Award can cover administrative support including salary, meetings and related travel among participating investigators, database generation and software development, purchase of computers, design of websites, teleconferences, and other costs directly associated with planning and developing the clinical trial or the review of the clinical protocol and consent form. Travel costs may not exceed $1,800 per investigator. *Funds may not be used to support laboratory or preclinical research.*

   Please note that there is no guarantee that funds will be available for Clinical Trial Awards in FY05.

   2. **Detailed Cost Estimate Forms and Justifications Instructions:** Applicants are cautioned to use discretion in budget requests. Budgets will also be reviewed during award negotiations. Complete justification must be provided for expenses in all categories. The Detailed Cost Estimate form and Justification for your proposal must be uploaded as a PDF file, separate from the proposal.
The following section provides instructions for preparing the Detailed Cost Estimate form. All amounts entered should be in U.S. dollars.

a. Personnel:

i. Name: Starting with the PI, list the names of all participants who will be involved in the project during the initial budget period, regardless of whether salaries are requested. Include all collaborating investigators, research associates, individuals in training, and support staff. Only ONE person may be identified as the PI of the proposal.

ii. Role on Project: Identify the role of each individual listed on the project. Describe his or her specific functions in the “Justification” section of the Detailed Cost Estimate form.

iii. Type of Appointment (Months): List the number of months per year reflected in an individual’s contractual appointment with the applicant organization. The DOD staff assumes that appointments at the applicant organization are full time for each individual. If an appointment is less than full time, e.g., 50%, note this with an asterisk (*) and provide a full explanation in the “Justification” section of the Detailed Cost Estimate form. Individuals may have split appointments (e.g., for an academic period and a summer period). For each type of appointment, identify and enter the number of months on separate lines.

iv. Annual Base Salary: Enter the annual institutional base salary for each individual listed for the project.

v. Percentage of Effort on Project: The qualifications of the PI and the amount of time that he or she and other professional personnel will devote to the research are important factors in selecting research proposals for funding. For each key staff member identified on the budget form, list the percentage of each appointment to be spent on this project.

vi. Salaries Requested: Enter the salaries in whole dollar figures for each position for which funds are requested. The salary requested is calculated by multiplying an individual’s institutional base salary by the percentage of effort on the project.

vii. Fringe Benefits: Fringe benefits may be requested in accordance with institutional guidelines for each position, provided the costs are treated consistently by the applicant organization for all sponsors. Documentation to support the fringe benefits should be provided.

viii. Totals: Calculate the totals for each position and enter these as subtotals in the columns indicated.

b. Consultant Costs: Regardless of whether funds are requested, provide the names and organizational affiliations of all consultants.

c. Major Equipment: It is the policy of the DOD that all commercial and non-profit recipients provide the equipment needed to support proposed research. In those rare cases where specific additional equipment is approved for commercial and non-profit organizations, such approved cost elements shall be separately negotiated. Moreover, it is expected that institutions will share 50% of the cost of equipment purchased for this research proposal when individual equipment costs are equal to or exceed $2,500.
d. Materials, Supplies, and Consumables: Funds from the Clinical Trial Development Award may not be used to support laboratory research. A general description and total estimated cost of expendable equipment and supplies are required. Itemize supplies in separate categories (e.g., glassware, chemicals, radioisotopes). Categories in amounts less than $1,000 do not need to be itemized. If animals are to be purchased, state the species, strain (if applicable), and the number to be used. If human cell lines are to be purchased, state the source and the description.

e. Travel Costs: Travel costs may not exceed $1,800 per year per investigator.

f. Research-Related Subject Costs: Itemize costs of subject participation in the research study. These costs are strictly limited to expenses specifically associated with the proposed study. The USAMRMC will not provide funds for ongoing medical care costs that are not related to a subject’s participation in the research study.

g. Other Expenses: Itemize other anticipated direct costs such as publication and report costs, rental for computers and other equipment (provide hours and rates), and communication costs. Unusual or expensive items should be fully explained and justified. Estimate the costs of publishing and reporting research results, including direct charges for clerical preparation, illustrations, reprints, and distribution.

h. Subaward Costs: A description of services or materials that are to be awarded by subcontract or subgrant is required. For awards totaling $10,000 or more, provide the following specific information:

- Identification of the type of award to be used (e.g., cost reimbursement, fixed price);
- Identification of the proposed subcontractor or subgrantee, if known, and an explanation of why and how the subcontractor or subgrantee was selected or will be selected;
- Whether the award will be competitive and, if noncompetitive, rationale to justify the absence of competition; and
- The proposed acquisition price.

i. Indirect Costs (overhead, general and administrative, and other): The most recent rates, dates of negotiation, base(s), and periods to which the rates apply should be disclosed along with a statement identifying whether the proposed rates are provisional or fixed.

j. Total Costs for the Entire Proposed Period of Support (second page of the Detailed Cost Estimate form): Enter the totals under each budget category for all additional years of support requested and itemize these totals in the “Justification” section of the Detailed Cost Estimate form. Note with an asterisk (*) and explain any significant increases or decreases from the initial year budget. All amounts should be in U.S. dollars. Total costs for the entire proposed period of support should equal the amount previously entered online in the Proposal Information https://cdmrp.org/proposals.

3. Justification (third page of the Detailed Cost Estimate form): Each item in the budget should be clearly justified under the “Justification” section of the Detailed Cost Estimate form.
G. Regulatory Requirements: Completed and signed copies of the “Certificate of Environmental Compliance” and “Principal Investigator Safety Program Assurance form” must be uploaded under the “Required Files” tab of the CDMRP eReceipt system as separate PDF files.

Do not submit other Regulatory Documents (Research Involving Human Subjects and/or Anatomical Substances; Research Involving Animals) with the proposal. Instead, the applicant should provide these documents to the USAMRMC only upon request.

H. USAMRAA Documents: The most current version of the institution’s negotiated “Rate Agreement,” the “Certifications and Assurances for Assistance Agreements,” and the “Representations for Assistance Agreements” must be uploaded by the Contract Representative from the Sponsored Programs Office (or equivalent). These documents must be uploaded as separate PDF files under the Contract Representative’s “My Profile” tab of the CDMRP eReceipt system prior to negotiations.

I. Submission Dates and Times: Proposals must be approved on the CDMRP eReceipt system by the Contract Representative at the applicant’s institution’s Sponsored Programs Office (or equivalent) by the deadline. If your proposal is either incomplete or not approved electronically before the deadline, it will not be considered for review. The eReceipt system will not accept data entry, file uploads, or approvals submitted after the 5:00 p.m. Eastern time April 13, 2004 deadline.

The timeline for Clinical Trial Development Awards is:

<table>
<thead>
<tr>
<th>Event</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Online Letter of Intent</td>
<td>Expected by <strong>February 17, 2004</strong></td>
</tr>
<tr>
<td>Online Proposal Information</td>
<td>Prior to proposal submission</td>
</tr>
<tr>
<td>Proposal Submission/Approval Deadline</td>
<td><strong>5:00 p.m. Eastern time April 13, 2004</strong></td>
</tr>
<tr>
<td>Proposal Review</td>
<td>May 2004</td>
</tr>
<tr>
<td>Notification Letter</td>
<td>Approximately 2 weeks after review</td>
</tr>
<tr>
<td>Award Start Date</td>
<td><strong>Between June 2004 and September 2004</strong></td>
</tr>
</tbody>
</table>

J. Electronic Submission Requirements: Electronic submission is required. Proposals will be accepted only as PDF files submitted through the CDMRP eReceipt system at [https://cdmrp.org/proposals](https://cdmrp.org/proposals).

Several steps are critical to successful proposal submission.

- The Proposal Information must be submitted prior to submission of the proposal. Applicants are encouraged to begin this part of the submission process early.
- The e-mail address of a Contract Representative from the Sponsored Programs Office (or equivalent) must be included.
- Applicants are encouraged to coordinate early with their Sponsored Programs Office.
- The Contract Representative from the Sponsored Programs Office (or equivalent) who is authorized to negotiate on behalf of the institution is required to provide final approval before the proposal is accepted.
- The eReceipt system will not accept data entry, file uploads, or approvals submitted after the 5:00 p.m. Eastern time April 13, 2004 deadline.
- Any supporting documentation that the applicant includes with the proposal must be incorporated into the PDF file prior to upload.
• Some items to be included in the proposal will need to be scanned. These items might include figures, tables, letters, or publications. All scanned documents, including figures, tables, and graphs, should be scanned at a resolution of 300-400 dpi or less.

• Budget Information includes the Detailed Cost Estimate form and the Budget Justification form. Budget Information must be uploaded under the “Required Files” tab of the CDMRP eReceipt system.

• The Regulatory documents required at submission include a completed, signed Certificate of Environmental Compliance and a completed, signed Principal Investigator Safety Program Assurance form. These must be uploaded under the “Required Files” tab of the CDMRP eReceipt system.

VI. PROPOSAL REVIEW INFORMATION

A. Proposal Review Process: Clinical Trial Development Award proposals will receive a single level of review by the PCRP Integration Panel (IP) to determine which proposals best fulfill the intent of the award mechanism. The IP, which is composed of scientists, clinicians, and consumer advocates, represents diverse disciplines and specialty areas, and the consumer members represent national advocacy constituencies. The PCRP IP will use the full Clinical Trial Development proposal to assess the scientific/technical merit and relevance of the submission to prostate cancer treatment, diagnosis, detection, or prevention.

B. Review Criteria: Clinical Trial Development Award proposals will be evaluated according to the following criteria:

• **Clinical Relevance:** Does the applicant provide a clear scientific rationale for the proposed clinical trial? Do existing preclinical science and/or preliminary clinical research support the relevance of the clinical trial to prostate cancer? Does the proposed clinical trial address an important problem related to the treatment, diagnosis, detection, or prevention of prostate cancer, and is it likely to have a substantial clinical impact?

• **Intervention:** Is the proposed intervention to be tested in the clinical trial adequately described and available? Is the intervention novel?

• **Clinical Trial:** Is the plan for the development of a clinical protocol within the time of the Clinical Trial Development Award appropriate? Is there a plan for obtaining both internal scientific review and local IRB approval(s) for the clinical protocol and consent form at the highest level possible within the institution, up to and including preliminary IRB approval, by the time of a Clinical Trial Award proposal submission? Are the preliminary sample sizes and patient accrual plans reasonable? Does the PI present evidence of access to an appropriate patient population? Is the outline of a clinical trial management plan present, and is it appropriate to the proposed clinical trial?

• **Principal Investigator and Personnel:** Does the PI have expertise in clinical prostate cancer research? Are the PI and other key personnel appropriately trained and well suited to carry out this work? Is there representation from all the areas of expertise needed to conduct the clinical trial successfully?

• **Institutional Commitment:** Is there evidence of institutional commitment to the proposed clinical trial at each participating institution?
Scientifically sound proposals that best fulfill the above criteria and most effectively address the unique focus and goals of the program will be selected by the IP and recommended to the Commanding General, USAMRMC, for funding.

VII. AWARD ADMINISTRATION INFORMATION

A. Award Notices: After the evaluation process is completed, every applicant will receive notification of the award status of his or her proposal. Applicants can expect to be notified of the agency’s decision by June 2004.

B. Administrative Requirements: All awards are made to organizations, not individuals. A PI should submit a proposal through, and be employed by or affiliated with, a university, college, non-profit research institute, commercial firm, or government agency (including military laboratories) in order to receive support. To be eligible for award, a prospective recipient should meet certain minimum standards pertaining to institutional support, financial resources, prior record of performance, integrity, organization, experience, operational controls, facilities, and conformance with safety and environmental statutes and regulations (Office of Management and Budget Circular A-110 and DOD Grant and Agreement Regulations). Any organization requesting receipt of an award from this announcement must be registered in the Central Contractor Registration (CCR) database. Access to the CCR online registration is through the CCR homepage at http://www.ccr.gov/.

Any change in the institution, the PI, and/or the SOW will require that the PI resubmit contact information. Any delay in the submission of updated information could result in a delay in the contracting and regulatory review and a subsequent delay in payment.

C. Award Negotiation: Award negotiation consists of discussions, reviews, and justifications of critical issues involving USAMRAA. A Contract Specialist from USAMRAA will contact the Contract Representative from the Sponsored Programs Office (or equivalent) who is authorized to negotiate contracts and grants at the applicant’s institution. As part of the negotiation process, additional documentation and justifications related to the proposed SOW and associated budgets may be required.

Note that the award start date will be determined during the negotiation process.

D. Regulatory Review:

1. Overview: Concurrent with the USAMRAA negotiations, the office of Surety, Safety and Environmental will review the Certificate of Environmental Compliance, and Principal Investigator Safety Program Assurance form submitted with the proposal. The USAMRMC RCQ office will review documents related to Research Involving Animal Use and Research Involving Human Subjects/Anatomical Substance Use submitted upon request to ensure that Army regulations are met.

2. Certificate of Environmental Compliance: The Certificate of Environmental Compliance must be submitted with the proposal. If multiple research sites/institutions are funded in your proposal, then a Certificate of Environmental Compliance for each site will be requested at a later date.

3. Safety Program Documents: The Principal Investigator Safety Program Assurance form must be submitted with the proposal.
A Facility Safety Plan is also required and will be requested at a later date. However, your institution may already have an approved Facility Safety Plan. To determine the status of approval, check the USAMRMC website at http://mrmc-www.army.mil/crprcqsohdfsplan.asp. If your institution is not listed on the aforementioned website, contact your Facility Safety Director/Manager to initiate completion of the institution-based Facility Safety Plan. Specific requirements for the Safety Program Plan can be found at http://mrmc-www.army.mil/docs/rcq/FY02FSPAppendix.doc.

If multiple research sites/institutions are funded in your proposal, then a Facility Safety Plan for each site/institution not listed in the aforementioned website will be requested at a later date.

4. **Research Involving Animal Use:** Animal use documents should not be submitted with the proposal and will be requested at a later date. Specific requirements for research involving animals can be found at http://mrmc-www.army.mil/docs/rcq/FY02AnimalAppendix.doc.

5. **Research Involving Human Subjects/Anatomical Substances:** Human Subjects and/or Anatomical Substances use documents should not be submitted with the proposal and will be requested at a later date. In addition to local IRB approval to conduct research involving human subjects and/or anatomical substances, a second tier of IRB review and approval is also required by the DOD. This second review is conducted by the Human Subjects Research Review Board (HSRRB), which is administered by the USAMRMC RCQ office. The HSRRB is mandated to comply with specific laws and directives governing all research involving human subjects that is conducted or supported by the DOD. These laws and directives are rigorous and detailed and will require information in addition to that supplied to the local review board. For example:

- **Intent to Benefit.** In the development of a research protocol for submission to the DOD, the applicant must specifically address, if applicable, the Intent to Benefit. An individual not legally competent to consent (e.g., minors) may not be enrolled in DOD-sponsored research unless the research is intended to benefit each and every subject enrolled in the study. Applicants should be aware that this law makes placebo-controlled clinical trials problematic because of the ‘intent to benefit’ requirement whenever participation is sought of subjects from whom consent must be obtained by the legally authorized representative.

- The DOD considers cell lines of human origin to be human anatomical substances. Use of these cell lines is subject to HSRRB review and approval.


6. **Award/Regulatory Approval:** Once an award is made, the applicant may not use, employ, or subcontract for the use of any human subjects, human anatomical substances, or use of laboratory animals without express written approval from the applicable USAMRMC RCQ office. USAMRMC RCQ will forward these express written approvals directly to the applicant with a copy furnished to the institution’s Sponsored Programs Office (or equivalent).

E. **Reporting:** All funded Clinical Trial Development Awards will require the timely delivery of a report during the development period. Reporting requirements for the Clinical Trial Development Award consist of an annual report that presents a detailed summary of issues and accomplishments for the funding period.
VIII. OTHER INFORMATION

A. Disclosure of Proprietary Information outside the Government: By submission of a proposal, the applicant understands that proprietary information may be disclosed outside the Government for the sole purpose of technical evaluation. The USAMRMC will obtain a written agreement from the evaluator that proprietary information in the proposal will only be used for evaluation purposes and will not be further disclosed or utilized. Funded proposals may be subject to public release under the Freedom of Information Act; proposals that are not selected for funding will not be subject to public release.

B. Government Obligation: Applicants are cautioned that only an appointed Contracting/Grants Officer may obligate the Government to the expenditure of funds. No commitment on the part of the Government to fund preparation of a proposal or to support research should be inferred from discussions with a technical project officer. Applicants who, or organizations that, make financial or other commitments for a research effort in the absence of an actual legal obligation signed by the USAMRAA Contracting/Grants Officer do so at their own risk.

C. Information Service: Offerors may use the technical reference facilities of the National Technical Information Service, 5285 Port Royal Road, Springfield, Virginia, 22161, for the purpose of surveying existing knowledge and avoiding needless duplication of scientific and engineering effort and the expenditure thereby represented. To the extent practical, all other sources should also be consulted for the same purpose.

D. Inquiry Review Panel: Applicants can submit a letter of inquiry to the USAMRMC in response to funding decisions made for a given proposal. Members of the CDMRP staff, USAMRMC Judge Advocate General staff, and USAMRAA Grants Officers constitute an Inquiry Review Panel and review each inquiry to determine whether factual or procedural errors in the review process have occurred, and if so, what action should be taken.

E. Title to Inventions and Patents: In accordance with the Bayh-Dole Act (35 USC 200 et seq.), title to inventions and patents resulting from such federally funded research may be held by the grantee or its collaborator, but the U.S. Government shall, at a minimum, retain nonexclusive rights for the use of such inventions. An investigator must follow the instructions in the assistance agreement concerning license agreements and patents.

F. J-1 Visa Waiver: It is the responsibility of the awardee to ensure that the research staff is able to complete the work without intercession by the DOD for a J-1 Visa Waiver on behalf of a foreign national in the United States under a J-1 Visa.

---

2Title 35, United States Code, Section 200 et seq.
## IX. ACRONYM LIST

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVI</td>
<td>Audio Video Interleave</td>
</tr>
<tr>
<td>CCR</td>
<td>Central Contractor Registration</td>
</tr>
<tr>
<td>CDMRP</td>
<td>Congressionally Directed Medical Research Programs</td>
</tr>
<tr>
<td>CFDA</td>
<td>Catalog of Federal Domestic Assistance</td>
</tr>
<tr>
<td>cGMP</td>
<td>Current Good Manufacturing Practices</td>
</tr>
<tr>
<td>CTDA</td>
<td>Clinical Trial Development Award</td>
</tr>
<tr>
<td>DOD</td>
<td>Department of Defense</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>HBCU</td>
<td>Historically Black Colleges and Universities</td>
</tr>
<tr>
<td>HBCU/MI</td>
<td>Historically Black Colleges and Universities/Minority Institutions</td>
</tr>
<tr>
<td>HSRRB</td>
<td>Human Subjects Research Review Board</td>
</tr>
<tr>
<td>IP</td>
<td>Integration Panel</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>M</td>
<td>Million</td>
</tr>
<tr>
<td>MB</td>
<td>Megabyte</td>
</tr>
<tr>
<td>MPEG</td>
<td>Moving Picture Experts Group</td>
</tr>
<tr>
<td>PCRP</td>
<td>Prostate Cancer Research Program</td>
</tr>
<tr>
<td>PDF</td>
<td>Portable Document Format</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>RCQ</td>
<td>Regulatory Compliance and Quality</td>
</tr>
<tr>
<td>SOW</td>
<td>Statement of Work</td>
</tr>
<tr>
<td>USAMRAA</td>
<td>US Army Medical Research Acquisition Activity</td>
</tr>
<tr>
<td>USAMRMC</td>
<td>US Army Medical Research and Materiel Command</td>
</tr>
<tr>
<td>USC</td>
<td>United States Code</td>
</tr>
<tr>
<td>WAV</td>
<td>Wave</td>
</tr>
</tbody>
</table>